153 related articles for article (PubMed ID: 1319782)
1. Quinolinic acid: effects on brain catecholamine and c-AMP content during L-dopa and reserpine administration.
Beskid M; Finkiewicz-Murawiejska L
Exp Toxicol Pathol; 1992 Apr; 44(2):66-9. PubMed ID: 1319782
[TBL] [Abstract][Full Text] [Related]
2. Effect of quinolinic acid administered during pregnancy on the brain of offspring.
Beskid M
Exp Toxicol Pathol; 1994 Oct; 46(4-5):323-7. PubMed ID: 7894243
[TBL] [Abstract][Full Text] [Related]
3. The antiparkinsonian drug budipine stimulates the activity of aromatic L-amino acid decarboxylase and enhances L-DOPA-induced dopamine release in rat substantia nigra.
Biggs CS; Fisher A; Starr MS
Synapse; 1998 Nov; 30(3):309-17. PubMed ID: 9776134
[TBL] [Abstract][Full Text] [Related]
4. [Interactions of cerebral serotonin and catecholamines].
Watanabe Y
Nihon Yakurigaku Zasshi; 1983 May; 81(5):365-83. PubMed ID: 6195056
[TBL] [Abstract][Full Text] [Related]
5. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
Biggs CS; Starr MS
Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
[TBL] [Abstract][Full Text] [Related]
6. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
Alachkar A; Brotchie JM; Jones OT
Neurosci Res; 2010 Sep; 68(1):44-50. PubMed ID: 20542064
[TBL] [Abstract][Full Text] [Related]
7. Effects of reserpine on activities and amounts of tyrosine hydroxylase and dopamine-beta-hydroxylase in catecholamine neuronal systems in rat brain.
Reis DJ; Joh TH; Ross RA
J Pharmacol Exp Ther; 1975 Jun; 193(3):775-84. PubMed ID: 239215
[TBL] [Abstract][Full Text] [Related]
8. [Effect of halothane on catecholamine metabolism in the brain stem of rats].
Schulte J
Arzneimittelforschung; 1976; 26(3):324-7. PubMed ID: 989321
[TBL] [Abstract][Full Text] [Related]
9. L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent.
Hornykiewicz O
Amino Acids; 2002; 23(1-3):65-70. PubMed ID: 12373520
[TBL] [Abstract][Full Text] [Related]
10. Modification of the cardiovascular effects of L-dopa by decarboxylase inhibitors.
Watanabe AM; Parks LC; Kopin IJ
J Clin Invest; 1971 Jun; 50(6):1322-8. PubMed ID: 5578236
[TBL] [Abstract][Full Text] [Related]
11. Depletion and recovery of catecholamines in several organs of rats treated with reserpine.
Martínez-Olivares R; Villanueva I; Racotta R; Piñón M
Auton Neurosci; 2006 Jul; 128(1-2):64-9. PubMed ID: 16723281
[TBL] [Abstract][Full Text] [Related]
12. A developmental role for catecholamines in Drosophila behavior.
Pendleton RG; Rasheed A; Paluru P; Joyner J; Jerome N; Meyers RD; Hillman R
Pharmacol Biochem Behav; 2005 Aug; 81(4):849-53. PubMed ID: 16051344
[TBL] [Abstract][Full Text] [Related]
13. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats.
Menzaghi F; Whelan KT; Risbrough VB; Rao TS; Lloyd GK
J Pharmacol Exp Ther; 1997 Jan; 280(1):393-401. PubMed ID: 8996220
[TBL] [Abstract][Full Text] [Related]
14. Evidence for inhibition of dopamine-beta-hydroxylase in vivo after sub-acute pyrazole treatment in rats.
MacDonald E; Pispa JP
Med Biol; 1977 Oct; 55(5):284-91. PubMed ID: 22792
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R
Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078
[TBL] [Abstract][Full Text] [Related]
16. Induction of dopamine biosynthesis by l-DOPA in PC12 cells: implications of L-DOPA influx and cyclic AMP.
Jin CM; Yang YJ; Huang HS; Lim SC; Kai M; Lee MK
Eur J Pharmacol; 2008 Sep; 591(1-3):88-95. PubMed ID: 18602388
[TBL] [Abstract][Full Text] [Related]
17. Effects of catecholamine depleting drugs and d-amphetamine on self-stimulation of the substantia nigra and locus coeruleus.
Cooper BR; Konkol RJ; Breese GR
J Pharmacol Exp Ther; 1978 Mar; 204(3):592-605. PubMed ID: 24729
[TBL] [Abstract][Full Text] [Related]
18. [Morphological picture of lesions to substantia nigra of rats following intracardial administration of quinolinic acid].
Markiewicz D; Beskid M
Pol Tyg Lek; 1989 Apr; 44(10-11):262-4. PubMed ID: 2530499
[TBL] [Abstract][Full Text] [Related]
19. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment.
Silva MA; Mattern C; Häcker R; Tomaz C; Huston JP; Schwarting RK
Synapse; 1997 Dec; 27(4):294-302. PubMed ID: 9372552
[TBL] [Abstract][Full Text] [Related]
20. Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid.
Harris CA; Miranda AF; Tanguay JJ; Boegman RJ; Beninger RJ; Jhamandas K
Br J Pharmacol; 1998 May; 124(2):391-9. PubMed ID: 9641558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
